Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative

ALLEGRI, RICARDO F.; CHREM MÉNDEZ, PATRICIO; CALANDRI, ISMAEL; COHEN, GABRIELA; MARTÍN, MARIA EUGENIA; RUSSO, MARÍA JULIETA; CRIVELLI, LUCIA; PERTIERRA, LUCIA; TAPAJÓZ, FERNANDA; CLARENS, MARÍA FLORENCIA; CAMPOS, JORGE; NAHAS, FEDERICO E.; VÁZQUEZ, SILVIA; SURACE, EZEQUIEL; SEVLEVER, GUSTAVO

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

ELSEVIER SCIENCE BV

Año: 2020 vol. 12

2352-8729

Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer´s Disease Neuroimaging Initiative (arg-ADNI) cohort.Methods: Twenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer´s type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (Aβ; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] Aβ42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan).Results: A+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control subjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of mild dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion rates to dementia after 5-year follow-up were 85% in A+T+N+ MCI patients and 50% in A-T-N+ patients.Conclusions: We present initial 5-year follow-up results of a regional ADNI based on AD biomarkers and the ATN classification.